GYRE THERAPEUTICS: Kaskela Law Announces Investigation of Gyre Therapeutics, Inc. (GYRE) and Encourages Shareholders to Contact the Firm
Gyre Therapeutics, Inc. (GYRE)
Company Research
Source: GlobeNewswire
PHILADELPHIA, April 20, 2026 (GLOBE NEWSWIRE) -- Kaskela Law LLC announces that it is investigating Gyre Therapeutics, Inc. (NASDAQ: GYRE) (“Gyre”) on behalf of the company’s investors.?? The investigation seeks to determine whether Gyre and/or the company’s officers and directors violated the securities laws or breached their fiduciary duties in connection with recent corporate actions.?? Gyre shareholders who would like to learn more about the investigation and their legal rights and options are encouraged to contact lead investigative attorney Adrienne Bell, Esq. at (484) 229 – 0750, by email at abell@kaskelalaw.com, or by filling out our online form at: https://kaskelalaw.com/case/gyre-therapeutics/ ABOUT KASKELA LAW: Kaskela Law exclusively represents investors in securities fraud, corporate governance, and merger & acquisition litigation on a contingent basis. For additional information about the firm, including our recent monetary recoveries for investors, please vi
Show less
Read more
Impact Snapshot
Event Time:
GYRE
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
GYRE alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
GYRE alerts
High impacting Gyre Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
GYRE
News
- Gyre Therapeutics (GYRE) was downgraded by Zacks Research from "hold" to "strong sell".MarketBeat
- Gyre Therapeutics Announces China's NMPA Grants Priority Review to the NDA for Hydronidone (F351) for CHB-Induced Liver Fibrosis Treatment [Yahoo! Finance]Yahoo! Finance
- Gyre Therapeutics Announces China’s NMPA Grants Priority Review to the NDA for Hydronidone (F351) for CHB-Induced Liver Fibrosis TreatmentGlobeNewswire
- Gyre Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update [Yahoo! Finance]Yahoo! Finance
- Gyre Therapeutics GAAP EPS of -$0.02 misses by $0.09, revenue of $37.2M beats by $1.76M [Seeking Alpha]Seeking Alpha
GYRE
Earnings
- 3/12/26 - Miss
GYRE
Sec Filings
- 4/27/26 - Form ARS
- 4/27/26 - Form DEF
- 4/27/26 - Form DEFA14A
- GYRE's page on the SEC website